5
Participants
Start Date
June 8, 2020
Primary Completion Date
September 23, 2024
Study Completion Date
September 23, 2024
BXQ-350
BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion in 28-day cycles
University of Kentucky Markey Cancer Center, Lexington
The Ohio State University Comprehensive Cancer Center, Columbus
University of Cincinnati Barrett Center, Cincinnati
Lead Sponsor
Collaborators (1)
CTI Clinical Trial and Consulting Services
OTHER
Bexion Pharmaceuticals, Inc.
INDUSTRY